Interferon (IFN) is a type of crucial cytokine, capable of directly participating in the antiviral immune response of epithelial cells, mediating the natural immune response to induce the expression of Interferon Stimulated Genes (ISG), hence, swiftly establishing the body's natural immune defense line against viral infections.

REGENXBIO Inc. shared the preliminary interim findings from a single-subject, researcher-led first-in-person study of RGX-181.

A striking 74% of assessable patients showcased a premier response of steady disease.

This inaugural human application (FIH) phase 1 examination, is exploring the efficiency of ISA104

Alpine Immune Sciences, Inc., has revealed the successful launch of the second IgA nephropathy (IgAN) dosage group in RUBY-3, a phase 1b/2a

Genexine,assessing the efficacy and security of eftansomatropin alfa (an exclusive long-acting growth hormone by Genexine, also referred to as GX-H9) in children suffering from growth hormone deficiency.

BenevolentAI has now informed that its initial subjects have been administered in Phase I first-in-human trials of its oral phosphodiesterase 10 (PDE10) inhibitor, BEN-8744.

This article summarized the latest R&D progress of Clofibrate, the Mechanism of Action for Clofibrate, and the drug target R&D trends for Clofibrate.

AbbVie, Inc. is a pharmaceutical organization that was founded in 2013 and is based in Illinois, United States.

PCSK9 is a serine protease synthesized by the liver, which can bind to and degrade the low-density lipoprotein receptor (LDL-R), reducing LDL-R's clearance of low-density lipoprotein cholesterol (LDL-C) in the serum.

Sugemalimab is an anti-PD-L1 monoclonal antibody developed by CStone Pharmaceuticals.

Recently, BridgeBio Pharma announced that its investigational treatment, acaracides, achieved its primary endpoint in the phase 3 clinical trial.